Peptide data sheet
Cagrilintide
GLP-1 · AM833 · Cagrilintide
Verdict
promisingThe promising label reflects genuine human trial data from the CagriSema program on body-weight endpoints; on its own, cagrilintide is an investigational research-grade peptide that is not FDA-approved and whose long-term picture is still open.
Quick answer
Cagrilintide (AM833) is a long-acting amylin-analog peptide commonly researched for appetite and body-weight endpoints. It is best known as the amylin half of CagriSema, an investigational combination with semaglutide that has real human trial data behind it. Cagrilintide is not FDA-approved; effects in humans are still being studied.
- Class
- Long-acting amylin-analog peptide (investigational)
- Half-life
- roughly 7 to 8 days (reported, supporting once-weekly research dosing)
- FDA status
- Not FDA-approved. Cagrilintide is an investigational research-grade peptide studied in clinical trials; it is sold for laboratory research use only and is not a finished prescription product.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The form used across the clinical trials and the CagriSema program. It carries essentially all of the human research context, and the reported side effects people discuss come from this route.
Standalone (cagrilintide alone)
Unproven
People also ask about cagrilintide on its own rather than paired with semaglutide. There is early human data here, but far less than for the combination, so the standalone picture is thinner than the CagriSema headlines suggest.